reason report
oasi show best class efficaci safeti
get pt
bottom line top-lin data oasi studi etrasimod
moderate-to-sever ulcer colitis/uc came better
expect hit primari secondari endpoint
surprisingli mg etrasimod also achiev underpow
hurdl clinic remiss measur
incid asymptomat atrioventricular av block transient
natur resolv may give investor paus
believ today data distinguish etrasimod favor versu
phosphat receptor modul term
efficaci safeti go forward investor anticip
addit data futur medic meet well arena
futur plan uc crohn diseas autoimmun
indic receptor modul benefici
link reiter op increas pt
etrasimod achiev stat sig improv primari endpoint
partial mayo score pm drug-induc rapid reduct t-
lymphocyt pt treat mg etrasimod show
point reduct pm vs seen pbo clear
dose-respons metric mg arm achiev stat sig
pm improv week arena also present
total mayo clinic score tm registr endpoint previou uc
studi also show dose-respons effect mg etrasimod
improv concord potenti better
receptor modul believ etrasimod could well differenti
oasi enrol difficult-to-treat pt use
tm mg etrasimod cohort still achiev clinic remiss
recal oasi studi power detect clinic
remiss howev use either pm tm
pt respect reach clinic remiss week
also stat sig respect etrasimod
remiss profil look competit versu agent
ozanimod xeljanz nr entyvio takeda nr humira
mp sinc pt enrol oasi studi refractori
difficult-to-treat treatment failur therapi
includ anti-tnf integrin antagonist entyvio believ
magnitud etrasimod efficaci impress
net debt total capit
compani inform leerink partner llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
although safeti profil mostli favor investor focu like
linger cardiac safeti investor ozanimod refuse-
to-fil rtf letter still fresh mind expect high
see lack cardiac effect link today data highlight pt
mg dose develop asymptomat av block shortli
first dose day although transient resolv
shortli emerg pt eventu discontinu trial
week reason unrel av block incid
degre av block type associ bradycardia pt
continu treatment eventu consid respond
end follow-up call management emphas effect av
node known on-target phenomenon profil etrasimod
still far cleaner ozanimod modul cite
lack need dose titrat side effect low discontinu
evid studi show pronounc case
av block remain optimist etrasimod potenc select
toward receptor manifest differenti safeti
cardiac profil compar modul link resolut
becom clearer futur medic meet asid cardiac
report advers event special interest
rais po previous posit data
opex also adjust assum intensifi develop plan
etrasimod although management provid opex guidanc
expect expens increas materi management aim expand
etrasimod beyond uc crohn diseas base previou
commun link initi uc studi possibl
avoid compet pt would anticip crohn diseas
program fast-track heel today data meanwhil
also mind on-going effort rare autoimmun indic
primari biliari cholang pbc pyoderma gangrenosum pg
also contribut futur expens updat project
believ arena suffici cash head
rate share outperform follow strateg reorgan led new
manag team see multipl opportun compani gener signific
sharehold valu develop potenti best class agent target blockbust
opportun improv exposur compani legaci belviq franchis
renegoti agreement eisai focus effort develop differenti
specialti medicin compani could commerci garner outsid interest
believ consid jnj recent acquisit atln much
motiv uptravi selexipag believ posit phase ralinepag data bode well
drug potenti gener signific revenu and/or investor enthusiasm likewis celg
op acquisit rcpt highlight valu could creat etrasimod
phase data multipl indic posit preclin etrasimod shown activ
receptor avoid receptor may translat
improv safeti profil open broader rang diseas posit etrasimod data
ulcer coliti uc could expand arena sight onto autoimmun diseas
rare preval phase studi initi pyoderma gangrenosum pg
primari biliari cholang pbc ralinepag etrasimod lengthi composition-of-matt
patent expir respect includ addit year
potenti patent term extens also develop peripher restrict
highli select full agonist cannabinoid receptor treatment pain associ
crohn diseas phase data expect
rate share outperform pt shift focu away legaci product
 belviq weight-loss toward proprietari pipelin innov medicin target
cardiopulmonari gastrointestin gi indic could creat signific sharehold valu
view leverag biolog mechan valid garner
attract valu ozanimod rcpt/celg op selexipag atln/jnj op
management focu smaller nich market also enabl compani independ pursuit
commerci larger market ulcer coliti uc could attract partner
alreadi establish space longer term could introduc follow-on candid
well execut life cycl manag lcm strategi expand proof concept
demonstr lead cardiopulmonari gi indic pursu diseases/afflict
share biolog mechan current assign probabl etrasimod uc
extraintestin manifest eim program pyoderma gangrenosum pg primari
biliari cholang pbc ralinepag assign probabl
pulmonari arteri hypertens pah pain associ crohn diseas respect
discount cash flow dcf analysi use discount rate termin growth rate
consist similar stage compani coverag achn
shift focu proprietari pipelin risk associ clinic trial
execut disappoint trial data regulatori review commerci success relev
meanwhil manag on-going effort divest/off-load belviq franchis could lead
unfavor term agreement may impact valuat
toll manufactur
impair long-liv asset
amort intang
interest incom expens net
valuat deriv liabil
cash equival
chang cash
chang asset liabil
proce sale equip
note payabl deerfield
issuanc common stock
issuanc prefer stock
issuanc debt
pain associ crohn diseas cd
updat clinic plan
reduct major cv event progress type
visual hallucin lewi bodi dementia
rem sleep behavior disord dementia lewi bodi
